KROS

Keros Therapeutics, Inc.

52.90 USD
+1.87 (+3.66%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Keros Therapeutics, Inc. stock is up 18.66% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 July’s closed higher than June. 100% of analysts rate it a buy.

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia.

  • Oppenheimer
    Tue Jun 25, 05:44
    buy
    initial
  • Truist Securities
    Tue Jun 18, 13:48
    buy
    confirm
  • HC Wainwright & Co.
    Tue Jun 18, 06:24
    buy
    confirm